HMGB1 regulates RANKL-induced osteoclastogenesis in a manner dependent on RAGE

Journal of Bone and Mineral Research

Volumn 23, Issue 7, 2008, Pages 1084-1096

  Zhou, Zheng ^a   Han, Jun Yan ^a   Xi, Cai Xia ^a   Xie, Jian Xin ^a   Feng, Xu ^b   Wang, Cong Yi ^a   Mei, Lin ^a   Xiong, Wen Cheng ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

High mobility group box 1; Osteoclastogenesis; RANKL; Receptor for advanced glycation endproducts

Indexed keywords

ACTIN; ADVANCED GLYCATION END PRODUCT; CYTOKINE; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN; INTEGRIN; NUCLEAR PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR FOR ADVANCED GLYCATION END PRODUCT; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CELL ACTIVATION; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOSKELETON; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MACROPHAGE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN SECRETION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; CELL DIVISION; DNA PRIMERS; FLUORESCENT ANTIBODY TECHNIQUE; HMGB1 PROTEIN; MICE; MICE, KNOCKOUT; OSTEOCLASTS; RANK LIGAND; RECEPTORS, IMMUNOLOGIC;

EID: 46249112770     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.080234     Document Type: Article

References (42)

1. Boyle WJ, Simonet WS, Lacey DL 2003 Osteoclast differentiation and activation. Nature 423:337-342.
2. Tanaka S, Takahashi N, Udagawa N, Tamura T, Akatsu T, Stanley ER, Kurokawa T, Suda T 1993 Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest 91:257-263.
3. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602.
4. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
5. Teitelbaum SL 2000 Osteoclasts, integrins, and osteoporosis. J Bone Miner Metab 18:344-349.
6. Takayanagi H 2005 Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med 83:170-179.
7. Kim N, Kadono Y, Takami M, Lee J, Lee SH, Okada F, Kim JH, Kobayashi T, Odgren PR, Nakano H, Yeh WC, Lee SK, Lorenzo JA, Choi Y 2005 Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med 202:589-595.
8. Ye H, Arron JR, Lamothe B, Cirilli M, Kobayashi T, Shevde NK, Segal D, Dzivenu OK, Vologodskaia M, Yim M, Du K, Singh S, Pike JW, Darnay BG, Choi Y, Wu H 2002 Distinct molecular mechanism for initiating TRAF6 signalling. Nature 418:443-447.
9. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL 2000 TNF-alpha induces osteoclastogenesis by direct Stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 106:1481-1488.
10. Koga T, Inui M, Inoue K, Kim S, Suematsu A, Kobayashi E, Iwata T, Ohnishi H, Matozaki T, Kodama T, Taniguchi T, Takayanagi H, Takai T 2004 Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 428:758-763.
11. Cella M, Buonsanti C, Strader C, Kondo T, Salmaggi A, Colonna M 2003 Impaired differentiation of osteoclasts in TREM-2-deficient individuals. J Exp Med 198:645-651.
12. Paloneva J, Mandelin J, Kiialainen A, Bohling T, Prudlo J, Hakola P, Haltia M, Konttinen YT, Peltonen L 2003 DAP12/ TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. J Exp Med 198:669-675.
13. Colonna M 2003 TREMs in the immune system and beyond. Nat Rev Immunol 3:445-453.
14. Yagi M, Miyamoto T, Sawatani Y, Iwamoto K, Hosogane N, Fujita N, Morita K, Ninomiya K, Suzuki T, Miyamoto K, Oike Y, Takeya M, Toyama Y, Suda T 2005 DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med 202:345-351.
15. Kim N, Takami M, Rho J, Josien R, Choi Y 2002 A novel member of the leukocyte receptor complex regulates osteoclast differentiation. J Exp Med 195:201-209.
16. Lotze MT, Tracey KJ 2005 High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat Rev Immunol 5:331-342.
17. Scaffidi P, Misteli T, Bianchi ME 2002 Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418:191-195.
18. Dumitriu IE, Baruah P, Valentinis B, Voll RE, Herrmann M, Nawroth PP, Arnold B, Bianchi ME, Manfredi AA, Rovere-Querini P 2005 Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol 174:7506-7515.
19. Dumitriu IE, Baruah P, Bianchi ME, Manfredi AA, Rovere-Querini P 2005 Requirement of HMGB1 and RAGE for the maturation of human plasmacytoid dendritic cells. Eur J Immunol 35:2184-2190.
20. Nawroth P, Bierhaus A, Marrero M, Yamamoto H, Stern DM 2005 Atherosclerosis and restenosis: Is there a role for RAGE? Curr Diab Rep 5:11-16.
21. Lue LF, Yan SD, Stern DM, Walker DG 2005 Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease. Curr Drug Targets CNS Neurol Disord 4:249-266.
22. Schmidt AM, Yan SD, Yan SF, Stern DM 2001 The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108:949-955.
23. Bierhaus A, Humpert PM, Stern DM, Arnold B, Nawroth PP 2005 Advanced glycation end product receptor-mediated cellular dysfunction. Ann N Y Acad Sci 1043:676-680.
24. Wang H, Ward MF, Fan XG, Sama AE, Li W 2006 Potential role of high mobility group box 1 in viral infectious diseases. Viral Immunol 19:3-9.
25. Dumitriu IE, Baruah P, Manfredi AA, Bianchi ME, Rovere-Querini P 2005 HMGB1: Guiding immunity from within. Trends Immunol 26:381-387.
26. Zhou Z, Immel D, Xi CX, Bierhaus A, Feng X, Mei L, Nawroth P, Stern DM, Xiong WC 2006 Regulation of osteoclast function and bone mass by RAGE. J Exp Med 203:1067-1080.
27. Li J, Wang H, Mason JM, Levine J, Yu M, Ulloa L, Czura CJ, Tracey KJ, Yang H 2004 Recombinant HMGB1 with cytokine-stimulating activity. J Immunol Methods 289:211-223.
28. McHugh KP, Hodivala-Dilke K, Zheng MH, Namba N, Lam J, Novack D, Feng X, Ross FP, Hynes RO, Teitelbaum SL 2000 Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 105:433-440.
29. Constien R, Forde A, Liliensiek B, Grone HJ, Nawroth P, Hammerling G, Arnold B 2001 Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line. Genesis 30:36-44.
30. Yang J, Shah R, Robling AG, Templeton E, Yang H, Tracey KJ, Bidwell JP 2007 HMGB1 is a bone-active cytokine. J Cell Physiol 14:730-739.
31. Charoonpatrapong K, Shah R, Robling AG, Alvarez M, Clapp DW, Chen S, Kopp RP, Pavalko FM, Yu J, Bidwell JP 2006 HMGB1 expression and release by bone cells. J Cell Physiol 207:480-490.
32. Matthay MA, Ware LB 2004 Can nicotine treat sepsis? Nat Med 10:1161-1162.
33. Wang H, Liao H, Ochani M, Justiniani M, Lin X, Yang L, Al-Abed Y, Metz C, Miller EJ, Tracey KJ, Ulloa L 2004 Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 10:1216-1221.
34. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A, Abraham E 2004 Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 279:7370-7377.
35. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL 2005 IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 115:282-290.
36. Kitaura H, Zhou P, Kim HJ, Novack DV, Ross FP, Teitelbaum SL 2005 M-CSF mediates TNF-induced inflammatory osteolysis. J Clin Invest 115:3418- 3427.
37. Orlova VV, Choi EY, Xie C, Chavakis E, Bierhaus A, Ihanus E, Ballantyne CM, Gahmberg CG, Bianchi ME, Nawroth PP, Chavakis T 2007 A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J 26:1129-1139.
38. Taniguchi N, Yoshida K, Ito T, Tsuda M, Mishima Y, Furumatsu T, Ronfani L, Abeyama K, Kawahara K, Komiya S, Maruyama I, Lotz M, Bianchi ME, Asahara H 2007 Stage-specific secretion of HMGB1 in cartilage regulates endochondral ossification. Mol Cell Biol 27:5650-5663.
39. Boyce BF, Li P, Yao Z, Zhang Q, Badell IR, Schwarz EM, O'Keefe RJ, Xing L 2005 TNF-alpha and pathologic bone resorption. Keio J Med 54:127-131.
40. Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A, Rubartelli A, Agresti A, Bianchi ME 2003 Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 22:5551-5560.
41. Chavakis T, Bierhaus A, Al-Fakhri N, Schneider D, Witte S, Linn T, Nagashima M, Morser J, Arnold B, Preissner KT, Nawroth PP 2003 The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: A novel pathway for inflammatory cell recruitment. J Exp Med 198:1507-1515.
42. Wee JL, Jackson DE 2005 The Ig-ITIM superfamily member PECAM-1 regulates the "outside-in" signaling properties of integrin alpha(IIb)beta3 in platelets. Blood 106:3816-3823.